Neladalkib shows promising efficacy in advanced ALK+ NSCLC, offering durable responses and manageable safety, potentially transforming treatment options.
Andrea Eleazar, MHS
Andrea Eleazar, MHS, is an assistant editor for Targeted Oncology, with interests in noncommunicable diseases, health equity research, and global health. Eleazar holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Articles by Andrea Eleazar, MHS
Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia, enhancing patient outcomes.
The FDA approves selumetinib for adults with neurofibromatosis type 1, offering new hope for treating inoperable plexiform neurofibromas.
Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.
Giredestrant shows promise as a groundbreaking treatment for early-stage breast cancer, significantly improving disease-free survival rates.
OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.
DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.
The FDA grants fast track designation to a new noninvasive diagnostic agent for clear cell renal cell carcinoma, promising improved patient outcomes.
Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.
The FDA clears the EXENT System, enhancing multiple myeloma diagnosis with automated workflows and improved sensitivity for clinical laboratories.
The FDA accepts 177Lu-edotreotide for GEP-NETs, showcasing significant survival benefits over everolimus in recent trials.
The FDA grants fast track designation to 4A10, a promising monoclonal antibody for treating relapsed acute lymphoblastic leukemia in children.
New data reveals detalimogene's promising efficacy and safety in treating high-risk bladder cancer, offering hope for improved patient outcomes.
MB-105 receives FDA RMAT designation, advancing treatment options for relapsed T-cell lymphoma and highlighting its promising clinical potential.
The FDA approves ziftomenib for relapsed mNPM1 AML, offering new hope with promising efficacy and safety data for patients.
FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic colorectal cancer, showing promising efficacy and safety in early trials.
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies.
The FDA clears the way for a pivotal phase 3 trial of lacutamab, promising new hope for patients with cutaneous T-cell lymphomas.
Tinostamustine receives FDA orphan drug designation, promising new hope for glioblastoma treatment with innovative dual-action mechanism.
The FDA fast-tracks AVZO-1418, a promising treatment for EGFR-mutated lung cancer, enhancing development and approval processes for patients in need.
A new treatment combination shows significant promise for patients with resistant gastrointestinal stromal tumors, improving survival rates and tolerability.
A recent study reveals survival trends in metastatic breast cancer, highlighting subtype-specific treatment needs and improved outcomes for HER2-positive patients.
Study data reveal key risk factors for pneumonitis in patients with metastatic breast cancer treated with T-DXd, highlighting the need for proactive management strategies.
New findings reveal promising antitumor responses in HER2-positive esophagogastric adenocarcinoma with a novel chemoimmunotherapy approach.
A recent study reveals that patient-reported side effect bother significantly predicts early treatment discontinuation in cancer therapies, highlighting the importance of patient feedback.
Innovations in cancer immunotherapy highlight the urgent need for effective management of immune-related toxicities, emphasizing precision medicine and interdisciplinary collaboration.
A recent study reveals that medication burden significantly increases acute care use in older metastatic prostate cancer patients on androgen receptor inhibitors.
Izalontamab shows promise as a safe treatment for advanced epithelial tumors, demonstrating early antitumor activity in a recent clinical trial.
New trial results reveal sacituzumab govitecan shows promise for HR+/HER2– metastatic breast cancer, despite missing primary survival goals.
New research identifies CD8+ PD-1+ TIM-3– LAG-3– TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.